US 2022/0105164 A1 · Method for Restoring Immune Tolerance In Vivo

Abstract

The present invention provides a method for restoring immune tolerance in vivo. The invention relates to the use of a recombinant gene encoding auto-antigens or parts thereof for restoring immune tolerance to the auto-antigens in vivo, under transcriptional control of polyomaviral early and late promoters. In a preferred embodiment, the invention relates to the use of recombinant polyomaviral gene delivery vector particles, such as simian virus 40 (SV40) viral vector particles encoding one or multiple auto-antigens or parts thereof under transcriptional control of the SV40 early and late promoter, for restoring immune tolerance to the auto-antigens in vivo. The invention also relates to compositions comprising recombinant genes or polyomaviral vectors and uses thereof as treatment for degenerative or dystrophic diseases.

Claims12

Dependent claims

Method for the production of recombinant polyomaviral vector particles not encoding a functional polyomaviral small T antigen, the method comprising:

providing a non-human primate SV40 permissive cell or cell line, wherein the SV40 permissive cell or cell line comprises a gene encoding a functional polyomaviral large T antigen stably integrated into the genome of the cell;
and
wherein the SV40 permissive cell or cell line does not comprise a gene encoding a functional polyomaviral small T antigen,
introducing into the SV40 permissive cell or cell line a polyomavirus DNA not encoding a functional polyomaviral small T antigen,
culturing the cell or cell line in a growth medium under conditions allowing the formation of recombinant polyomaviral vector particles, and
harvesting the recombinant polyomaviral vector particles from the cell culture.

3 more elements

Dependencies are inferred from the claim text.

Method for Restoring Immune Tolerance In Vivo

Life of this patent

Method for Restoring Immune Tolerance In Vivo

Life of this patent

Abstract

Claims12